The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Open accessThe DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The study aimed to enroll 400 subjects with early mild cognitive impairment (MCI), 200 subjects with early AD, and 200 normal control subjects; $67 million funding was provided by both the public and private sectors, including the National Institute on Aging, 13 pharmaceutical companies, and 2 foundations that provided support through the Foundation for the National Institutes of Health. This article reviews all papers published since the inception of the initiative and summarizes the results as of February 2011. The major accomplishments of ADNI have been as follows: (1) the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are consistent with disease trajectories predicted by β‐amyloid cascade (Hardy, J Alzheimers Dis 2006;9(Suppl 3):151–3) and tau‐mediated neurodegeneration hypotheses for AD, whereas brain atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change depending on region and disease severity; (3) the assessment of alternative methods of diagnostic categorization. Currently, the best classifiers combine optimum features from multiple modalities, including MRI, [18 F]‐fluorodeoxyglucose‐PET, CSF biomarkers, and clinical tests; (4) the development of methods for the early detection of AD. CSF biomarkers, β‐amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in mildly symptomatic or even nonsymptomatic subjects, and are leading candidates for the detection of AD in its preclinical stages; (5) the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes. Baseline cognitive and/or MRI measures generally predicted future decline better than other modalities, whereas MRI measures of change were shown to be the most efficient outcome measures; (6) the confirmation of the AD risk loci CLU, CR1, and PICALM and the identification of novel candidate risk loci; (7) worldwide impact through the establishment of ADNI‐like programs in Europe, Asia, and Australia; (8) understanding the biology and pathobiology of normal aging, MCI, and AD through integration of ADNI biomarker data with clinical data from ADNI to stimulate research that will resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby advancing efforts to find disease‐modifying drugs for AD; and (9) the establishment of infrastructure to allow sharing of all raw and processed data without embargo to interested scientific investigators throughout the world. The ADNI study was extended by a 2‐year Grand Opportunities grant in 2009 and a renewal of ADNI (ADNI‐2) in October 2010 through to 2016, with enrollment of an additional 550 participants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“It is now generally accepted that the initial AD pathology develops in situ while the patient is cognitively normal, sometimes termed the “preclinical stage” [18,19].”
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Self-citationAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“Once transgenicmice expressingAb in their brains were available [22], development of treatments to slow the progression of AD began in earnest.”
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citation
Cited by
The cognitive neuroscience of ageing
Grady, C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3256 · Cited by 1,286
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationMagnetoencephalography for Brain Electrophysiology and Imaging
Baillet, S. (2017) · Nature Neuroscience · doi:10.1038/nn.4504 · Cited by 992
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data
the Alzheimer’s Disease Neuroimaging Initiative, E. C., Thompson, P. M., Stein, J. L., Medland, S. E., Hibar, D. P., Vasquez, A. A., Renteria, M. E., Toro, R., Jahanshad, N., Schumann, G., et al. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9269-5 · Cited by 838
“The Alzheimer ’ s Disease Neuroimaging Initiative (ADNI), for example (Weiner et al. 2012), scanned around 800 people in its first phase, including healthy elderly people, individuals with mild cognitive impairment and patients with Alzheimer ’ s disease.”
Self-citationHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects
Moradi, E., Pepe, A., Gaser, C., Huttunen, H., & Tohka, J. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.002 · Cited by 708
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
“Until the advent of amyloid imaging and the unmasking of amyloid plaques in up to 30% of individuals with normal cognition [42], this lack of complete correlation between the presence of AD pathologies in the OE and clinical diagnosis of AD dementia had diminished the interest and effort of further diagnostic and mech…”
BackgroundSelf-citationConsortium, T. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00062 · Cited by 516
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.10.006 · Cited by 479
Self-citationDeep Learning Based Imaging Data Completion for Improved Brain Disease Diagnosis
Li, R., Zhang, W., Suk, H.-I., Wang, L., Li, J., Shen, D., & Ji, S. (2014) · Lecture Notes in Computer Science · doi:10.1007/978-3-319-10443-0_39 · Cited by 469
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease
Gray, K. R., Aljabar, P., Heckemann, R. A., Hammers, A., & Rueckert, D. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.065 · Cited by 456
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationWard, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000354370 · Cited by 426
Metal dyshomeostasis and oxidative stress in Alzheimer’s disease
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.014 · Cited by 436
Jahanshad, N., Kochunov, P. V., Sprooten, E., Mandl, R. C., Nichols, T. E., Almasy, L., Blangero, J., Brouwer, R. M., Curran, J. E., de Zubicaray, G. I., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.061 · Cited by 393
“Some multicenter studies, such as the Alzheimer's Disease Neuroimaging Initiative, or ADNI (Weiner et al., 2012), harmonized their image acquisition protocols at the outset, but a far larger sample can be amassed if data can be combined from multiple studies that were initially planned and performed independently.”
BackgroundSelf-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“The National Institute on Aging-Alzheimer’s Association (NIA-AA) has developed criteria for MCI due to AD that use biomarkers to determine the likelihood of AD pathology and classify patients accordingly [350].”
BackgroundSelf-citationEffectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging
Nir, T. M., Jahanshad, N., Villalon-Reina, J. E., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.07.006 · Cited by 348
“…et al., 2003; Chetelat and Baron, 2003; Thompson et al., 2003; Anderson et al., 2005; Apostolova and Thompson, 2008; Bakkour et al., 2009; Risacher et al., 2009; Apostolova et al., 2010; Desikan et al., 2010a; Desikan et al., 2010b; Chiang et al., 2011; Weiner et al., 2012; Leung et al., 2013).”
Self-citationAyton, S., Faux, N. G., Bush, A. I., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7760 · Cited by 327
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Self-citationClinical applications of the functional connectome
Castellanos, F. X., Di Martino, A., Craddock, R. C., Mehta, A. D., & Milham, M. P. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.083 · Cited by 312
Böhle, M., Eitel, F., Weygandt, M., & Ritter, K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00194 · Cited by 291
“In the last decade, those markers have frequently been employed in machine learning settings to allow for predictions on an individual level (Klöppel et al., 2008; Orrù et al., 2012; Weiner et al., 2013; Ritter et al., 2015, 2016).”
BackgroundMicroglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers
DeKosky, S. T., Blennow, K., Ikonomovic, M. D., & Gandy, S. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.36 · Cited by 268
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 260
Pfefferbaum, A., Rohlfing, T., Rosenbloom, M. J., Chu, W., Colrain, I. M., & Sullivan, E. V. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.008 · Cited by 256
“…focus on healthy seniors (age 60 years and older), who had served as the comparison group for age-related dementing disorders, or use data taken from publicly available data sources, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) (e.g., Fjell et al., 2009a; Weiner et al., 2012).”
BackgroundMethodInfluentialImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Donohue, M. C., Green, R. C., Harvey, D., Jack, C. R., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.04.005 · Cited by 239
“accuracy has been further enhanced by the addition of other neuroimaging and clinical measures [11].”
InfluentialSelf-citationMachine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
Self-citationAnalysis of sampling techniques for imbalanced data: An n = 648 ADNI study
Dubey, R., Zhou, J., Wang, Y., Thompson, P. M., & Ye, J. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.005 · Cited by 204
“Data imbalance is also ubiquitous inworldwide ADNI type initiatives from Europe, Japan and Australia, etc. (Weiner et al., 2012).”
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.9 · Cited by 195
The anatomical basis of dystonia: Current view using neuroimaging
Lehéricy, S., Tijssen, M. A. J., Vidailhet, M., Kaji, R., & Meunier, S. (2013) · Movement Disorders · doi:10.1002/mds.25527 · Cited by 194
“Longitudinal, multicenter studies designed to develop standardized quantitative imaging markers for dystonia, in combination with clinical and genetic biomarkers, could also expand the application of imaging to the investigation of the anatomical and physiological bases and differences of the different forms of dyston…”
BackgroundKorolev, I. O., Symonds, L. L., Bozoki, A. C., & Initiative, A. D. N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0138866 · Cited by 194
“In this study, we develop a multivariate prognostic model [18] for predicting MCI-to-dementia progression using baseline data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) [19].”
MethodSelf-citationVeitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationLongitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180
“The ADNI was launched in 2004 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration, private pharmaceutical companies and non-profit organizations, which has been extensively reviewed elsewhere [40] (see additional information in h…”
Self-citationSørensen, L., Igel, C., Pai, A., Balas, I., Anker, C., Lillholm, M., & Nielsen, M. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.025 · Cited by 179
A second X chromosome contributes to resilience in a mouse model of Alzheimer’s disease
Davis, E. J., Broestl, L., Abdulai-Saiku, S., Worden, K., Bonham, L. W., Miñones-Moyano, E., Moreno, A. J., Wang, D., Chang, K., Williams, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5677 · Cited by 176
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Neurosteroids as regenerative agents in the brain: therapeutic implications
Brinton, R. D. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.31 · Cited by 163
Data-driven models of dominantly-inherited Alzheimer’s disease progression
(2018) · doi:10.1093/brain/awy050 · Cited by 145
Weiner, M. W., Veitch, D. P., Miller, M. J., Aisen, P. S., Albala, B., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12797 · Cited by 126
Self-citationKochunov, P., Jahanshad, N., Sprooten, E., Nichols, T. E., Mandl, R. C., Almasy, L., Booth, T., Brouwer, R. M., Curran, J. E., de Zubicaray, G. I., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.03.033 · Cited by 133
“Ideally, harmonization of data collection should occur at the onset of the multicenter imaging study as demonstrated by the efforts of the Alzheimer's Disease Neuroimaging Initiative (Weiner et al., 2012) and others (Teipel et al.”
Self-citationCellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease
Arnold, S. E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D. A., Negash, S., Leurgans, S. E., Schneider, J. A., Buchman, A. S., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.004 · Cited by 123
Mulder, E. R., de Jong, R. A., Knol, D. L., van Schijndel, R. A., Cover, K. S., Visser, P. J., Barkhof, F., & Vrenken, H. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.01.058 · Cited by 122
“To assess reproducibility, we employed the unique set of “ back-to-back ” (BTB) MPRAGE scans that are available as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset (Jack et al., 2008; Mueller et al., 2005; Weiner et al., 2012).”
Whole-genome analyses of whole-brain data: working within an expanded search space
Medland, S. E., Jahanshad, N., Neale, B. M., & Thompson, P. M. (2014) · Nature Neuroscience · doi:10.1038/nn.3718 · Cited by 119
Imaging in sepsis-associated encephalopathy—insights and opportunities
Stubbs, D. J., Yamamoto, A. K., & Menon, D. K. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.177 · Cited by 118
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Self-citationToward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress
Gandy, S., & DeKosky, S. T. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092611-084441 · Cited by 110
Suárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109
Self-citationDonovan, N. J., Wadsworth, L. P., Lorius, N., Locascio, J. J., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.006 · Cited by 106
“Weiner) (see Supplemental Digital Content; available online).(24) The ADNI study sample, as previously described,(1) comprises 812 subjects (diagnoses at baseline: 229 CN, 395 MCI, 188 AD dementia) who underwent serial cognitive, clinical, neuropsychiatric, and neuroimaging assessments at baseline and at 6- or 12month…”
Diffusion-MRI in neurodegenerative disorders
Goveas, J., O’Dwyer, L., Mascalchi, M., Cosottini, M., Diciotti, S., De Santis, S., Passamonti, L., Tessa, C., Toschi, N., & Giannelli, M. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.04.006 · Cited by 104
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99
“Individuals who have evidence of abundant AD pathology but do not meet clinical criteria for mild cognitive impairment (MCI) or dementia, thus preserving their cognitive functioning, have been described by a range of allied concepts such as ‘‘pathological aging’’, ‘‘preclinical AD’’, ‘‘asymptomatic AD’’, and ‘‘resilie…”
Vision function abnormalities in Alzheimer disease
Tzekov, R., & Mullan, M. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.10.002 · Cited by 94
Military risk factors for Alzheimer's disease
Weiner, M. W., Friedl, K. E., Pacifico, A., Chapman, J. C., Jaffee, M. S., Little, D. M., Manley, G. T., McKee, A., Petersen, R. C., Pitman, R. K., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.005 · Cited by 87
“[45] Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC,”
BackgroundSelf-citationCairns, N. J., Perrin, R. J., Franklin, E. E., Carter, D., Vincent, B., Xie, M., Bateman, R. J., Benzinger, T., Friedrichsen, K., Brooks, W. S., et al. (2015) · Neuropathology · doi:10.1111/neup.12205 · Cited by 86
“org/) was established to determine the relationships among the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of sporadic, predominantly late-onset, Alzheimer disease (LOAD) (1,2).”
InfluentialSelf-citationRudrauf, D. (2014) · Advances in Neuroscience · doi:10.1155/2014/462765 · Cited by 74
“A progressive pattern of diffuse atrophy [57] and abnormal resting metabolism [60] develops consecutively with collateral oxidative and inflammatory stress, synaptic loss and neuronal loss, especially in association cortices.”
BackgroundInfluentialCSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
Self-citationGenome‐wide association study of Alzheimer's disease endophenotypes at prediagnosis stages
Chung, J., Wang, X., Maruyama, T., Ma, Y., Zhang, X., Mez, J., Sherva, R., Takeyama, H., Initiative, T. A. D. N., Lunetta, K. L., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.006 · Cited by 67
“Details about collection of CSF biomarkers, brain MRI scan data, and neuropsychological tests are reported elsewhere [12–15].”
Brendel, M., Kleinberger, G., Probst, F., Jaworska, A., Overhoff, F., Blume, T., Albert, N. L., Carlsen, J., Lindner, S., Gildehaus, F. J., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00008 · Cited by 66
“This motivates a worldwide effort to find new biomarkers predicting future cognitive decline in patients with suspicion of early AD, and likewise for use as outcome measures in clinical trials of innovative disease-modifying agents (Weiner et al., 2012).”
BackgroundCilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60
MacQueen, G. M., Hassel, S., Arnott, S. R., Addington, J., Bowie, C. R., Bray, S. L., Davis, A. D., Downar, J., Foster, J. A., Frey, B. N., et al. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180036 · Cited by 57
Li, K., O'Brien, R., Lutz, M., Luo, S., & Initiative, T. A. D. N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.004 · Cited by 44
“All ri building models for predicting AD based on a single marker, or a combination of multiple markers, which captures the heterogeneity among subjects and detects the disease progression of subjects at risk [1].”
BackgroundDean, K., Walker, Z., & Jenkinson, C. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s145676 · Cited by 34
“It has been noted in the literature that, up to now, no PROMs developed specifically existed for MCI 7,8 and that the lack of consistency in outcome measures used has made it difficult to compare and interpret the results of many of the interventional studies that have been carried out in this…”
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
“As with fluid biomarkers, inter-lab standardization is paramount but can be quite difficult due to the use of different makes and models of scanners, each with their own idiosyncrasies (52).”
BackgroundPredicting Alzheimer’s Disease Using Combined Imaging-Whole Genome SNP Data
Kong, D., Initiative, A. F. T. A. D. N., Giovanello, K. S., Wang, Y., Lin, W., Lee, E., Fan, Y., Murali Doraiswamy, P., & Zhu, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150164 · Cited by 26
“The growing public threat of Alzheimer’s disease (AD) has raised the urgency to discover and validate prognostic biomarkers that may identify subjects at greatest risk for future cognitive decline and accelerate the testing of preventive strategies [1, 2].”
Self-citationCortical signatures of cognition and their relationship to Alzheimer’s disease
Initiative, F. T. A. D. N., Gross, A. L., Manly, J. J., Pa, J., Johnson, J. K., Park, L. Q., Mitchell, M. B., Melrose, R. J., Inouye, S. K., & McLaren, D. G. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9180-5 · Cited by 25
Diffusion tensor magnetic resonance imaging of the brain in app transgenic mice: A cohort study.
Müller, H.-P., Kassubek, J., Vernikouskaya, I., Ludolph, A. C., Stiller, D., & Rasche, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067630 · Cited by 22
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
“…longitudinal patient-level data from two open-access natural history studies in patients diagnosed with amnestic MCI—the Alzheimer’s Disease Neuroimaging Initiative (ADNI)-1 and ADNI-2 57 —to develop an HV neuroimaging-informed clinical trial enrichment tool for amnestic MCI clinical trials.”
BackgroundMethodInfluentialSheng, J., Zhu, H., Zhou, R., Zhang, Q., Wang, J., & Ying, Z. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149691 · Cited by 4
HINN prioritizes multi-omics biomarkers associated with cognitive decline
Vashishath, Y., Beaver, S. A., Saeed, F., & Bozdag, S. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag741
Metadata
- Authors
- Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., Morris, J. C., Petersen, R. C., Saykin, A. J., Schmidt, M. E., Shaw, L., Siuciak, J. A., Soares, H., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-11-03
- Volume
- 8
- Issue
- 1S
- Pages
- S1-68
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4249565903
- Cited by
- 476
- References
- 222
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.